Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million. The move represented the second big shift in the U.S. generics market in as many days, coming 24 hours after Lannett Co. Inc., of Philadelphia, said it was purchasing Kremers Urban Pharmaceuticals Inc., of Princeton, N.J. – the U.S. specialty generic pharmaceuticals subsidiary of UCB SA, of Brussels – for $1.23 billion up front and undisclosed contingency payments.